MX375183B - Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas. - Google Patents
Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.Info
- Publication number
- MX375183B MX375183B MX2014006574A MX2014006574A MX375183B MX 375183 B MX375183 B MX 375183B MX 2014006574 A MX2014006574 A MX 2014006574A MX 2014006574 A MX2014006574 A MX 2014006574A MX 375183 B MX375183 B MX 375183B
- Authority
- MX
- Mexico
- Prior art keywords
- same
- methods
- formulations
- combinations
- acamprosate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004047 acamprosate Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 230000000701 neuroleptic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566550P | 2011-12-02 | 2011-12-02 | |
| US201261649137P | 2012-05-18 | 2012-05-18 | |
| PCT/US2012/067507 WO2013082573A1 (en) | 2011-12-02 | 2012-12-02 | Acamprosate formulations, methods of using the same, and combinations comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014006574A MX2014006574A (es) | 2015-02-10 |
| MX375183B true MX375183B (es) | 2025-03-06 |
Family
ID=48536156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006574A MX375183B (es) | 2011-12-02 | 2012-12-02 | Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2785337B1 (enExample) |
| JP (1) | JP6407720B2 (enExample) |
| KR (1) | KR102055859B1 (enExample) |
| CN (1) | CN104379138B (enExample) |
| AU (1) | AU2012345659B2 (enExample) |
| BR (1) | BR112014013374B1 (enExample) |
| CA (1) | CA2863265C (enExample) |
| HK (2) | HK1207563A1 (enExample) |
| IL (1) | IL232935B (enExample) |
| MX (1) | MX375183B (enExample) |
| RU (1) | RU2671399C2 (enExample) |
| SG (1) | SG11201403785UA (enExample) |
| WO (1) | WO2013082573A1 (enExample) |
| ZA (1) | ZA201404826B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| CN105431144A (zh) | 2013-06-05 | 2016-03-23 | 思康脑侒股份有限公司 | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 |
| WO2020206107A1 (en) * | 2019-04-03 | 2020-10-08 | Synchroneuron Inc. | Formulations |
| US12260944B2 (en) * | 2019-10-11 | 2025-03-25 | Hoffmann-La-Roche Inc. | Drug dosage determination devices and methods |
| IL304905A (en) * | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | IRAK4 joints and their uses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4562911B2 (ja) * | 1998-01-13 | 2010-10-13 | シンクロニュ−ロン，エルエルシ− | 遅発性ジスキネジア及び他の運動障害の治療方法 |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| MXPA04010956A (es) * | 2003-01-30 | 2005-01-25 | Roehm Gmbh | Forma de dosis farmaceutica y metodo para la produccion de la misma. |
| RU2284814C1 (ru) * | 2005-04-08 | 2006-10-10 | Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" | Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| WO2008073282A2 (en) * | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
| DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| EP2540294B1 (en) * | 2010-02-22 | 2016-08-03 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
| CN101987081B (zh) * | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| CA2850468C (en) * | 2010-09-28 | 2019-08-13 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
-
2012
- 2012-12-02 HK HK15108166.4A patent/HK1207563A1/xx unknown
- 2012-12-02 SG SG11201403785UA patent/SG11201403785UA/en unknown
- 2012-12-02 CN CN201280068973.8A patent/CN104379138B/zh active Active
- 2012-12-02 BR BR112014013374-3A patent/BR112014013374B1/pt not_active IP Right Cessation
- 2012-12-02 MX MX2014006574A patent/MX375183B/es active IP Right Grant
- 2012-12-02 EP EP12853036.7A patent/EP2785337B1/en active Active
- 2012-12-02 RU RU2014126879A patent/RU2671399C2/ru active IP Right Revival
- 2012-12-02 WO PCT/US2012/067507 patent/WO2013082573A1/en not_active Ceased
- 2012-12-02 JP JP2014544970A patent/JP6407720B2/ja active Active
- 2012-12-02 HK HK15100399.0A patent/HK1199841A1/xx unknown
- 2012-12-02 CA CA2863265A patent/CA2863265C/en active Active
- 2012-12-02 KR KR1020147018413A patent/KR102055859B1/ko active Active
- 2012-12-02 AU AU2012345659A patent/AU2012345659B2/en active Active
-
2014
- 2014-06-02 IL IL232935A patent/IL232935B/en active IP Right Grant
- 2014-06-30 ZA ZA2014/04826A patent/ZA201404826B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201404826B (en) | 2016-07-27 |
| JP2015500812A (ja) | 2015-01-08 |
| IL232935A0 (en) | 2014-07-31 |
| CA2863265C (en) | 2020-04-14 |
| RU2014126879A (ru) | 2016-01-27 |
| KR102055859B1 (ko) | 2019-12-13 |
| AU2012345659A1 (en) | 2014-07-24 |
| IL232935B (en) | 2020-11-30 |
| CN104379138B (zh) | 2021-12-07 |
| AU2012345659B2 (en) | 2017-09-28 |
| EP2785337A4 (en) | 2015-04-22 |
| BR112014013374A2 (pt) | 2017-06-13 |
| EP2785337A1 (en) | 2014-10-08 |
| BR112014013374B1 (pt) | 2022-10-11 |
| KR20140121394A (ko) | 2014-10-15 |
| WO2013082573A1 (en) | 2013-06-06 |
| SG11201403785UA (en) | 2014-10-30 |
| CN104379138A (zh) | 2015-02-25 |
| RU2671399C2 (ru) | 2018-10-31 |
| BR112014013374A8 (pt) | 2021-08-31 |
| JP6407720B2 (ja) | 2018-10-17 |
| HK1207563A1 (en) | 2016-02-05 |
| AU2012345659A8 (en) | 2014-08-07 |
| EP2785337B1 (en) | 2021-01-20 |
| MX2014006574A (es) | 2015-02-10 |
| HK1199841A1 (en) | 2015-07-24 |
| CA2863265A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| MX377553B (es) | Composicion farmaceutica estable y metodos de uso de la misma. | |
| MX394383B (es) | Composiciones y metodos que comprenden variante de enzima lipolitica. | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
| CR20140200A (es) | Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos | |
| UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
| UY35661A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen | |
| UY32659A (es) | Pirazinilpirazoles | |
| MX2012008717A (es) | Composiciones para el cuidado oral. | |
| BR112016006048A8 (pt) | composições antimicrobianas | |
| HN2010001537A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| BR112015008389A2 (pt) | compostos úteis na síntese de compostos de benzamida | |
| MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| MX375183B (es) | Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas. | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| CL2012003265A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo. | |
| BR112013023575A2 (pt) | derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |